Filter by: patients
Home > Community Treatment Reports and Side Effects > Parkinson's Phase 3 Study IPX066 APEX-PD Treatment Report
What is Parkinson's Phase 3 Study IPX066 APEX-PD?

NCT00880620 is a placebo-controlled study to evaluate the safety and efficacy of drug IPX066 in subjects with Parkinson's Disease. Other study IDs: IPX066-B08-05, APEX-PD.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Parkinson's Disease 2 2 Efficacy_major

See 1 patient currently using Parkinson's Phase 3 Study IPX066 APEX-PD

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 2
None
 0

Commonly reported side effects, conditions, and hospitalizations associated with Parkinson's Phase 3 Study IPX066 APEX-PD

Dry mouth (xerostomia) 1

Reported Schedules

  15 other daily
  1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Using Parkinson's Phase 3 Study IPX066 APEX-PD (multiple reasons could be selected)
Reason # Patients Percentage of patients
Course of treatment ended 1   Course of treatment ended: 100%

See all 1 patient who’ve stopped using Parkinson's Phase 3 Study IPX066 APEX-PD

Reported Duration See details about how long patients take this treatment ▼

Stopped Using Parkinson's Phase 3 Study IPX066 APEX-PD

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Parkinson's Phase 3 Study IPX066 APEX-PD

Always
 2 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Parkinson's Phase 3 Study IPX066 APEX-PD

Very
 0 0%
Somewhat
 0 0%
A little
 1 50%
Not at all
 1 50%

Cost

Paid out of pocket

Cost of Parkinson's Phase 3 Study IPX066 APEX-PD

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 1 100%

Report created on May 27, 2012.